DUCENTIS BIOTHERAPEUTICS
Ducentis is a pre-clinical stage company aiming to develop novel therapies for inflammation and autoimmune disease. Ducentis' target is the CD200/CD200R axis which imparts a deactivating signal to activated immune cells in both the innate and adaptive arms of the immune system. Potential therapeutic targets include transplant rejection and autoimmune and inflammatory diseases affecting the lungs, liver, kidney, eye, bone, and cartilage.
DUCENTIS BIOTHERAPEUTICS
Industry:
Biopharma Biotechnology Health Care Medical Pharmaceutical
Founded:
2015-03-01
Address:
Witney, Oxfordshire, United Kingdom
Country:
United Kingdom
Website Url:
http://www.ducentisbio.com
Total Employee:
1+
Status:
Active
Contact:
+441993880504
Email Addresses:
[email protected]
Total Funding:
880 K GBP
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apache Microsoft Exchange Online Office 365 Mail
Similar Organizations
AimVion A/S
AimVion A/S is a privately held research and development company focused on peptide based drugs for inflammatory and autoimmune diseases.
AZTherapies
AZTherapies is a clinical stage biotech company developing breakthrough treatments for neuroinflammation-related diseases.
Celator Pharmaceuticals
Celator Pharmaceuticals is a biopharmaceutical company developing therapies to treat cancer, using the drug ratio technology platform.
PIQUR Therapeutics
PIQUR Therapeutics is a Swiss pharmaceutical company focusing on the discovery and development of anti-cancer drugs.
Redoxis
Redoxis is a preclinical CRO with focus on inflammation and autoimmune conditions.
Soligenix
Soligenix is a biopharmaceutical company that develops biodefense vaccines and therapeutics to treat rare diseases.
Synovo GmbH
Synovo GmbH is a drug discovery company with a primary focus on inflammation and innate immune processes
Current Employees Featured
Founder
Investors List
Capital Cell
Capital Cell investment in Angel Round - Ducentis BioTherapeutics
Oxford Technology Management
Oxford Technology Management investment in Angel Round - Ducentis BioTherapeutics
Oxford Technology Management
Oxford Technology Management investment in Seed Round - Ducentis BioTherapeutics
Official Site Inspections
http://www.ducentisbio.com
- Host name: a67c48129651a0940.awsglobalaccelerator.com
- IP address: 76.223.67.189
- Location: Seattle United States
- Latitude: 47.54
- Longitude: -122.3032
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98108
More informations about "Ducentis BioTherapeutics"
Ducentis BioTherapeutics - Crunchbase Company …
Ducentis is a pre-clinical stage company aiming to develop novel therapies for inflammation and autoimmune disease. Ducentis' target is the CD200/CD200R axis which imparts a deactivating signal to activated immune cells in both the …See details»
Arcutis Announces Acquisition of Ducentis BioTherapeutics Ltd.
“This acquisition is an important step in realizing our vision of becoming the leading, innovation-driven medical dermatology company, and leverages our deep dermatology expertise and …See details»
Org Chart Ducentis BioTherapeutics - The Official Board
The organizational chart of Ducentis BioTherapeutics displays its 5 main executives including Philippe LenobleSee details»
Ducentis BioTherapeutics - Overview, News & Similar companies ...
Sep 7, 2022 Popular Searches ducentis biotherapeutics Ltd Ducentis BioTherapeutics Ducentisbio htmlDucentis BioTherapeutics Ltd SIC Code 87,873 NAICS Code 54,541 Show …See details»
Ducentis BioTherapeutics acquired by Arcutis Biotherapeutics
Sep 8, 2022 Acquiring Organization: Arcutis Biotherapeutics Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing medical dermatology for unmet …See details»
Arcutis Biotherapeutics buys Ducentis BioTherapeutics …
Sep 8, 2022 “This acquisition is an important step in realizing our vision of becoming the leading, innovation-driven medical dermatology company, and leverages our deep dermatology expertise and capabilities across the …See details»
Arcutis Announces Acquisition of Ducentis BioTherapeutics Ltd.
Sep 7, 2022 Leverages Arcutis’ deep dermatology expertise and broad biologics experience to accelerate Ducentis’ lead compound, DS-234, in atopic dermatitisLead indication, atopic …See details»
Ducentis Biotherapeutics | VentureRadar
Website: http://www.ducentisbio.com/ Develops novel therapies for inflammation and autoimmune diseases using a unique mechanism to control excessive immune responses ...See details»
LifeArc portfolio company Ducentis acquired for $400M - LifeArc
Sep 8, 2022 LifeArc today announced that its portfolio company Ducentis BioTherapeutics, a preclinical-stage biotechnology company focused on developing novel therapies for …See details»
Ducentis BioTherapeutics - Contacts, Employees, Board Members, …
Ducentis is a pre-clinical stage company that aims to develop novel therapies for inflammation and autoimmune disease.See details»
LifeArc portfolio company Ducentis BioTherapeutics acquired by …
Sep 8, 2022 First exit for LifeArc Ventures, the largest investor in Ducentis, recognising the transformational potential of its science; Ducentis lead pre-clinical asset DS-234 is being …See details»
Arcutis Announces Acquisition of Ducentis BioTherapeutics Ltd.
Sep 7, 2022 Arcutis Biotherapeutics, Inc. Leverages Arcutis’ deep dermatology expertise and broad biologics experience to accelerate Ducentis’ lead compound, DS-234, in atopic dermatitisSee details»
Ducentis Company Profile 2024: Valuation, Investors ... - PitchBook
Ducentis General Information Description. Developer of novel therapies designed to provide treatment for inflammation and autoimmune diseases. The company offers an axis that is …See details»
Ducentis BioTherapeutics - Craft
Ducentis is a pre-clinical stage company developing therapies for inflammation and autoimmune disease. Its target is the CD200/CD200R axis which imparts a deactivating signal to activated …See details»
Ducentis Biotherapeutics | CipherBio
Explore Ducentis Biotherapeutics's investment information, scientific platforms, therapeutic approaches, indications and more here!See details»
Arcutis Announces Acquisition of Ducentis BioTherapeutics Ltd.
Sep 7, 2022 Leverages Arcutis’ deep dermatology expertise and broad biologics experience to accelerate Ducentis’ lead compound, DS-234, in atopic dermatitis LeadSee details»
Ducentis BioTherapeutics - Funding, Financials, Valuation & Investors
How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised . Lead Investors . Aug 1, 2017: Angel Round - …See details»
Arcutis To Acquire Ducentis BioTherapeutics | citybiz
Sep 8, 2022 CD200R has been validated as a target in atopic dermatitis, with recent preclinical and clinical data providing evidence of a durable biologic response, even after discontinuation …See details»
www.ducentisbio.com
Www.ducentisbio.comSee details»
Co-founder, CEO @ Ducentis BioTherapeutics - Crunchbase
Dr Philip Huxley is the founder of Ducentis BioTherapeutics, and a specialist in turning basic science into clinical candidates. He obtained his PhD in theoretical chemistry in 1982 and has …See details»